| http://www.w3.org/ns/prov#value | - We are pleased with the progress of our clinical pipeline and remain on track to achieve the goals we have previously outlined, including reporting interim data from the sotatercept trial in beta-thalassemia next week at the American Society of Hematology Annual Meeting, said John Knopf, Ph.D., Chief Executive Officer of Acceleron.
|
